As mutated FLT3 is considered an attractivetarget for the treatmentof AML, several small-molecule inhibitors have been investigated aspotential therapeutics.8−10 First-generation inhibitors comprise nonspecificreceptor tyrosine kinase inhibitors, such as sunitinib, sorafenib,and midostaurin, originally developed for other indications. Here, FLT3 is linked to acute myeloid leukemia.